Omeros Corp (OMER)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

201 ELLIOTT AVENUE WEST SEATTLE, WA 98119

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors.

Data as of 2021-10-09 09:39:07 -0400
Market Cap418.721 Million Shares Outstanding62.496 Million Avg 30-day Volume1.475 Million
P/E Ratio-3.00333 Dividend Yield0.0 EPS-2.28
Price/Sales6.16 Debt to Equity-0.59 EBITDA-112.325 Million
Price to Book Value-2.17 Forward PE-4.54 Enterprise Value772.64 Million
Total Cash73.658 Million Current Debt47.697 Million Gross Profit85.537 Million
BETA0.92503 52-week High/Low23.85 / 6.52 Next Earnings Date2021-11-08 Price to Cash FLow (P/CF) -34.3589
Data provided by IEX Cloud
View SEC Filings from OMER instead.

View recent insider trading info

Funds Holding OMER (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding OMER BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

10 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HANISH ARNOLD C

15,000 2021-09-08 1

DEMOPULOS GREGORY A MD CHAIRMAN, CEO & PRESIDENT

550,000 2021-07-02 4

JACOBSEN MICHAEL A VP FINANCE AND CAO

75,000 2021-07-02 4

CANCELMO PETER B VP, GEN. COUNSEL & CORP. SEC.

75,000 2021-07-02 2

DEMOPULOS PETER A MD

198,516 2021-02-22 1

HOOD LEROY E. MD PHD

74,390 2021-02-12 1

CABLE THOMAS J.

35,067 2021-01-13 1

ASPIRI RAY

0 2020-06-05 0

SHAH RAJIV

0 2020-06-05 0

BUMOL THOMAS F.

0 2020-06-05 0

ZUMWALT KURT

  • Director
1,000 2020-02-10 0

KELBON MARCIA S. VP PATENT AND GENERAL COUNSEL

  • Officer
210,645 2019-06-07 0

SPIEGELMAN DANIEL K

  • Director
0 2012-06-01 0

TRIPET JEAN-PHILIPPE

  • Director
0 2011-05-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

HANISH ARNOLD C see footnote

2021-09-09 17:19:28 -0400 2021-09-08 M 10,000 $9.44 a 10,000 indirect 1.8554 2.2393 2.2393 6 -0.5118 4

HANISH ARNOLD C

2021-09-09 17:19:28 -0400 2021-09-08 M 10,000 d 5,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
OMEROS CORP OMER 2021-10-15 22:15:04 UTC -0.6992 0.7692 2200000
OMEROS CORP OMER 2021-10-15 21:45:03 UTC -0.7029 0.7729 2200000
OMEROS CORP OMER 2021-10-15 21:15:03 UTC -0.7029 0.7729 2200000
OMEROS CORP OMER 2021-10-15 20:45:03 UTC -0.7033 0.7733 2200000
OMEROS CORP OMER 2021-10-15 20:15:03 UTC -0.7033 0.7733 2200000
OMEROS CORP OMER 2021-10-15 19:45:03 UTC -0.7033 0.7733 2200000
OMEROS CORP OMER 2021-10-15 19:15:04 UTC -0.7033 0.7733 2200000
OMEROS CORP OMER 2021-10-15 18:45:03 UTC -0.7064 0.7764 2200000
OMEROS CORP OMER 2021-10-15 18:15:03 UTC -0.7064 0.7764 2200000
OMEROS CORP OMER 2021-10-15 17:45:03 UTC -0.7064 0.7764 2200000
OMEROS CORP OMER 2021-10-15 17:15:03 UTC -0.7064 0.7764 2200000
OMEROS CORP OMER 2021-10-15 16:45:03 UTC -0.6909 0.7609 2200000
OMEROS CORP OMER 2021-10-15 16:15:03 UTC -0.6909 0.7609 2200000
OMEROS CORP OMER 2021-10-15 15:45:03 UTC -0.6909 0.7609 2200000
OMEROS CORP OMER 2021-10-15 15:15:03 UTC -0.6909 0.7609 2200000
OMEROS CORP OMER 2021-10-15 14:45:02 UTC -0.6785 0.7485 2200000
OMEROS CORP OMER 2021-10-15 14:15:03 UTC -0.6785 0.7485 2200000
OMEROS CORP OMER 2021-10-15 13:45:03 UTC -0.6785 0.7485 2200000
OMEROS CORP OMER 2021-10-15 13:15:03 UTC -0.6785 0.7485 2200000
OMEROS CORP OMER 2021-10-15 12:45:03 UTC -0.6785 0.7485 2200000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund OMER -53636.0 shares, $-814730.84 2021-05-28 N-PORT
THE LAZARD FUNDS, INC.- Lazard Enhanced Opportunities Portfolio OMER -8865.0 shares, $-131556.6 2021-06-30 N-PORT
JNL Series Trust- JNL Multi-Manager Alternative Fund OMER -63923.0 shares, $-948617.32 2021-06-30 N-PORT
AQR Funds- AQR Diversified Arbitrage Fund OMER -189128.0 shares, $-2806659.52 2021-06-30 N-PORT

Elevate your investments